Testing a new drug for rheumatoid arthritis
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This trial tests a new medication (BMS-986454) for people with rheumatoid arthritis who haven't responded well enough to methotrexate. It aims to see if the drug is safe and how it works in the body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old when your rheumatoid arthritis started.
- You must have been diagnosed with rheumatoid arthritis based on standard medical criteria (ACR/EULAR 2010).
- You must have swelling in at least one hand or wrist joint at the screening visit and the day before the study starts.
- You must have tried methotrexate but it didn't work well enough (incomplete responder).
- You cannot have any other serious medical condition (like heart, lung, kidney, or liver problems) that would make the study risky for you, as decided by the study doctor.
- You must not have severe rheumatoid arthritis as measured by a special score (DAS28-CRP) at screening or the day before the study starts.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a new investigational drug called Natrunix, when combined with your usual methotrexate, can improve symptoms of moderate to severe rheumatoid arthritis. The goal is to reduce joint pain and swelling and help you feel better.
This study tests a new medication called AZD1163 for people with rheumatoid arthritis (RA) that hasn't responded well enough to standard treatments. It aims to see if the drug can safely reduce joint swelling and pain.
This study tests a new investigational drug called SR-878 for people with rheumatoid arthritis. It aims to see if the drug is safe and tolerable. You may join if you are between 18 and 60, have RA for at least 3 months, and take a stable dose of methotrexate.
This study tests a new drug, RO7790121, for people with rheumatoid arthritis (RA) who have not gotten better with or could not tolerate common treatments like TNF inhibitors or JAK inhibitors. It aims to see if the drug is safe and can help reduce joint pain and swelling.
This study tests a new oral medication, PTC844, for people with active rheumatoid arthritis whose current treatments have not worked well enough or who haven't tried any yet. The goal is to see if it can reduce joint pain and swelling.
This trial tests a new one-time IV treatment (BX-U001) for people with rheumatoid arthritis that hasn't improved with standard therapies. The goal is to check its safety and how well people tolerate it.
Hear when a new Rheumatoid arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.